Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone 42 mg met the primary endpoint of change ...

Intra-Cellular Therapies' stock (ITCI) surged over 35% in premarket trading on Monday, poised for its best-ever open and a record high, even as broader market futures grappled with weak tech stock ...

Corstasis Therapeutics Inc. ( a late clinical-stage innovator of therapies that enhance options for the treatment of fluid overload in patients with cardiorenal and hepatic diseases, with the intent ...

Throughout the last three months, 18 analysts have evaluated Intra-Cellular Therapies (NASDAQ:ITCI), offering a diverse set of opinions from bulli ...

Intra-Cellular Therapies (NASDAQ:ITCI) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ...

Shares of Intra-Cellular Therapeutics were up 14.8% Tuesday morning after the healthcare company released top-line phase 3 trial information regarding its depression therapy, Caplyta (lumateperone).

Intra-Cellular promptly launched CAPLYTA in its newly approved indication. Revenues for Q1, 2022 more than doubled compared to its Q1, 2021 as shown by its excerpt from its Q1, 2022 10-Q (p. 16 ...

Intra-Cellular Therapies stock trades for just above $45 a share and has a ~$4.5B market cap. Click here to read what lies ahead for ITCI stock.

Intra-Cellular's net loss deepened to $72.1 million ($0.78 per share), from first quarter 2021's $52.7 million deficit. However, analysts -- and likely investors -- had been bracing for worse.

Johnson & Johnson will acquire Intra-Cellular Therapies for $132 per share in a deal that values the company at $14.6 billion. The acquisition includes FDA-approved CAPLYTA for schizophrenia and ...

Analysts have set 12-month price targets for Intra-Cellular Therapies, revealing an average target of $100.93, a high estimate of $130.00, and a low estimate of $74.00.